089sek
-6,1 %
Date:2024-04-26Time:17:29:00Latest report:Q4-2023List:First NorthTicker:ASAP
Market Cap:20 msekEnterprise Value:18 msekNet Sales:- msekEarnings:-12,9 msekEmployees:0ISIN:SE0011641794

Ratios

10-year key figure history for Asarina Pharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Asarina Pharma with index and moving average MA50 and MA200.

Stockprice:0,89
MA50:0,92
MA200:0,91
Price/MA200:-1,7 %
RSI (14):46,5
Price/MA50:-3,5 %

Description

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Pharmaceuticals